

- An acceptable photo ID issued by a federally recognized ⁴ Tribal Nation/ Indian Tribe, including Enhanced Tribal Cards (ETCs).

- HSPD-12 PIV card.

- Foreign government-issued passport.

- Canadian provincial driver's license or Indian and Northern Affairs Canada card.

- Transportation worker identification credential.

- U.S. Citizenship and Immigration Services Employment Authorization Card (I-766).

- U.S. Merchant Mariner Credential.

- Veteran Health Identification Card (VHIC).

Comments: Time is allocated on the agenda to hear public comments from 4:35 p.m. to 5:00 p.m. The time for oral comments will be limited to two (2) minutes per individual. To provide a public comment, please register by emailing your name to napa@hhs.gov by Monday, July 27, 2026. Registered commenters will receive both a dial-in number and a link to join the meeting virtually; individuals will have the choice to either join virtually via the link, or to call in only by using the dial-in number. **Note:** There may be a 30–45 second delay in the livestream video presentation of the conference. For this reason, if you have pre-registered to submit a public comment, it is important to connect to the meeting by 4:20 p.m. to ensure that you do not miss your name and allotted time when called. If you miss your name and allotted time to speak, you may not be able to make your public comment. Public commenters will not be admitted to the virtual meeting before 4:05 p.m. but are encouraged to watch the meeting at www.hhs.gov/live. Should you have questions during the session, please email napa@hhs.gov and someone will respond to your message as quickly as possible.

- To ensure accuracy, please submit a written copy of oral comments for the record by emailing napa@hhs.gov by Wednesday, August 5, 2026. These comments will be shared on the website and reflected in the meeting minutes.

- In lieu of oral comments, formal written comments may be submitted for the record by Wednesday, August 5, 2026, to Maria-Theresa Okafor, Ph.D., MCG, OASPE, 200 Independence Avenue SW, Room 438F.7, Washington, DC 20201. Comments may also be sent to napa@hhs.gov. Those submitting

written comments should identify themselves and any relevant organizational affiliations.

Authority: 42 U.S.C. 11225; Section 2(e)(3) of the National Alzheimer's Project Act. The panel is governed by provisions of Public Law 92–463, as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory committees.

Cynthia L. Goss,

Deputy Assistant Secretary for Planning and Evaluation (Health Policy), Performing the Delegable Duties of the Assistant Secretary for Planning and Evaluation.

[FR Doc. 2026–14907 Filed 7–22–26; 8:45 am]

BILLING CODE 4150–28–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the **SUPPLEMENTARY INFORMATION** section of this Notice to Modala Bio, Inc. (Modala), headquartered in Delaware.

DATES: Only written comments and/or applications for a license which are received by the National Center for Advancing Translational Sciences' Office of Strategic Alliances on or before August 24, 2026 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Jasmine Kalsi, M.S., Licensing and Patenting Manager, Office of Strategic Alliances, Telephone: 301–435–0129; Email: jasmine.kalsi@nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property

“RXFP1 AGONISTS”

(1) U.S. Provisional Application No. 63/780,976 and NIH Reference No.: E–145–2024–0–US–02 filed 31 March 2025.

(2) U.S. PCT Application No. PCT/US2026/021648, filed March 31, 2026,

and NIH Reference No.: E–145–2024–0–PC–01.

The patent rights in these inventions have been either assigned and/or exclusively licensed to the government of the United States of America, Florida International University (FIU), and University of South Florida (USF).

The prospective exclusive license territory may be worldwide, and the field of use may be limited to the following:

“NCGC00846044, TRND00589605, TRND00600099 and TRND00658394, including any related analogs for the treatment or prevention of: cancers, cardiovascular, pulmonary, and fibrotic diseases.”

The present invention is directed to novel relaxin receptor (RXFP1 receptor) small molecule agonists useful for treating relaxin-related disorders including fibrosis, certain cancers, vascular calcifications, including atherosclerosis, and heart failure. The RXFP1 agonists of this invention possess a number of advantages not found in earlier RXFP1 agonists. These properties include, for example, improved bioavailability, low toxicity, and better activity in RXFP1-dependent biological functional assays.

The development of small-molecule agonists of RXFP1 would have numerous benefits and will allow investigating additional therapeutic applications where chronic administration is required. NCATS has identified a series of small-molecule agonists of RXFP1 which are potent, highly selective, easy to synthesize, and with reasonable metabolic and physical properties. The molecules of this invention display similar efficacy as the natural hormone in several functional assays. Mutagenesis studies have mapped the specific regions responsible for relaxin receptor activation by these compounds to an allosteric site on the receptor. Finally, these compounds display good in vivo pharmacokinetic properties and are currently being evaluated in vivo.

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within thirty (30) days from the date of this published Notice, the National Center for Advancing Translational Sciences receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than

⁴ <https://www.federalregister.gov/documents/2021/01/29/2021-01606/indian-entities-recognized-by-and-eligible-to-receive-services-from-the-united-states-bureau-of>.

those in the form of a license application, will not be treated confidentially and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: July 17, 2026.

Joni L. Rutter,

Director, Office of the Director, National Center for Advancing Translational Sciences, National Institutes of Health.

[FR Doc. 2026-14848 Filed 7-22-26; 8:45 am]

BILLING CODE 4167-05-P

DEPARTMENT OF HOMELAND SECURITY

Transportation Security Administration

Intent To Request Extension From OMB of One Current Public Collection of Information: Transportation Security Officer Medical Questionnaire

AGENCY: Transportation Security Administration, DHS.

ACTION: 60-Day notice.

SUMMARY: The Transportation Security Administration (TSA) invites public comment on one currently approved Information Collection Request (ICR), Office of Management and Budget (OMB) control number 1652-0032, abstracted below, which we will submit to OMB for an extension in compliance with the Paperwork Reduction Act (PRA). The ICR describes the nature of the information collection and its expected burden. The collection involves using questionnaires to collect medical information from candidates and licensed physicians or other licensed health practitioners for the job of Transportation Security Officer (TSO) to ensure candidates are qualified to perform TSO duties pursuant to 49 U.S.C. 44935.

DATES: Send your comments by September 21, 2026.

ADDRESSES: Comments may be emailed to TSAPRA@tsa.dhs.gov or delivered to the TSA PRA Officer, Information Technology, TSA-11, Transportation Security Administration, 6595 Springfield Center Drive, Springfield, VA 20598-6011.

FOR FURTHER INFORMATION CONTACT: Christina A. Walsh at the above address, or by telephone (571) 227-2062.

SUPPLEMENTARY INFORMATION:

Comments Invited

In accordance with the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*), an agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a valid OMB control number. The ICR documentation will be available at <https://www.reginfo.gov> upon its submission to OMB. Therefore, in preparation for OMB review and approval of the following information collection, TSA is soliciting comments to—

(1) Evaluate whether the proposed information requirement is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

(2) Evaluate the accuracy of the agency's estimate of the burden;

(3) Enhance the quality, utility, and clarity of the information to be collected; and

(4) Minimize the burden of the collection of information on those who are to respond, including using appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Information Collection Requirement

OMB Number 1652-0032; *Security Officer Medical Questionnaire*. TSA collects relevant medical information from TSO candidates who have successfully completed certain prior steps in the hiring process. This information is used to assess whether the TSO candidates meet the medical qualification standards the agency has established pursuant to 49 U.S.C. 44935.

On June 8, 2026, OMB approved TSA's request for an emergency revision of this information collection, allowing for the move from a paper-based Security Officer Medical Questionnaire (SOMQ) to an online version of the SOMQ and to introduce a paper-based TSO Medical Clearance Form. *See* ICR Reference Number: 202606-1652-003. The revision was necessary to address urgent hiring requirements for front-line, mission critical TSO positions. TSA is seeking renewal of this information collection for the maximum 3-year approval period.

The online SOMQ, like the prior paper SOMQ, enables TSA to collect the information necessary to assist in making determinations regarding candidates' medical and physical abilities to successfully perform the job. The scope of this determination provides a candidate's current and past medical history, including visual and

aural acuity, physical coordination, and motor skills to be able to: (a) distinguish on screening equipment monitors the appropriate imaging standard; (b) distinguish each color displayed on every type of screening equipment and explain what each color signifies; (c) hear and respond to the spoken voice and to audible alarms in an active checkpoint environment; (d) perform physical searches by efficiently and thoroughly manipulating and handling baggage containers, and other objects; (e) perform pat-downs or hand-held metal detector searches of individuals with sufficient dexterity and capacity to thoroughly conduct the procedures over an individual's entire body; and (f) demonstrate a daily fitness for duty without impairment due to illegal drugs, sleep deprivation, medication, or alcohol.

The TSO Medical Clearance Form also helps TSA ascertain the candidates' medical and physical abilities to successfully perform the job. The TSO Medical Clearance Form is completed by a licensed physician or other licensed health practitioner to indicate whether the candidate is able to perform a list of the duties of a TSO. The candidate's licensed physician or other licensed health practitioner also uses the TSO Medical Clearance Form to provide the results of the medical examination, including vital signs, visual acuity, peripheral vision, color vision and hearing.

TSA estimates an average annual number of respondents completing the online SOMQ and TSO Medical Clearance Form is approximately 18,000 respondents. The total annual hour burden of this collection is 43,200 hours (9,000 SOMQ + 34,200 TSO Medical Clearance Form). TSA estimates the average time to complete the SOMQ online tool is 9,000 hours. In addition, TSA estimates the annual burden hour to undergo the medical examination required to evaluate a candidate using the TSO Medical Clearance form is 34,200 hours, which includes the exam, printing and submitting the form, round-trip travel time and time spent in the waiting room.

Dated: July 20, 2026.

Christina A. Walsh,

Paperwork Reduction Act Officer, Information Technology, Transportation Security Administration.

[FR Doc. 2026-14855 Filed 7-22-26; 8:45 am]

BILLING CODE 9110-05-P